Synonyms: EMD 1195686 | EMD-1195686 | Xadago®
safinamide is an approved drug (EMA (2015), FDA (2017))
Compound class:
Synthetic organic
Comment: Safinamide is an alpha-aminoamide. The clinically administered formulation may be the mesylate salt (PubChem CID 3038502).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Safinamide is approved as an adjunct to dopamine agonist or levodopa/carbidopa therapy in patients with Parkinson's disease experiencing "off" episodes. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Safinamide's main action is to inhibit monoamine oxidase B (MAOB) which reduces degradation of dopamine [3], but may also inhibit reuptake of dopamine and act to inhibit glutamate release, and block sodium and calcium channels. Inhibition of MAOB effectively increases dopamine levels in the brain, providing some relief from the motor symptoms of Parkinson's disease. The drug helps to reduce the motor fluctuations which can occur when the effect of levodopa therapy wears off. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |